Lung cancer is one of the most significant health problems globally due to its high prevalence and mortality rates. Innovative treatment regimens are needed to improve survival rates and reduce mortality from this disease in clinical practice. Objective. To evaluate the effectiveness and safety of a combination therapy consisting of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) in the treatment of advanced non-small cell lung cancer (NSCLC). We also aim to identify the optimal patient population for whom this treatment regimen would be most beneficial in real-world clinical practice. Material and methods. A retrospective analysis of the medical records of 58 patients who received a combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) at medical institutions in the Chelyabinsk region between January 2020 and November 2023 was conducted. Results. The median age of the 58 participants was 62 years (range: 38—84). The median duration of ABCP treatment was 11.3 months. Disease control (partial response or stable disease) was achieved in 84.2% (48) of patients. The median progression-free survival was 15.1 months (95% confidence interval (CI): 11.7—20.3). The mPFS among patients with brain metastases was 24.8 months (95% CI: 19.2—40.7)), p=0.05, and the median overall survival has not been reached yet. Conclusion. The study demonstrated that ABCP therapy shows high antitumor efficacy in real-world clinical settings for patients with advanced NSCLC. The objective response rate and progression-free and overall survival were equivalent or superior to those observed in the IMpower150 study. A subgroup analysis showed that patients with brain metastases can benefit from this combination therapy. The safety profile of ABCP was characterized by an acceptable profile with a very low incidence of immune-mediated adverse events. The data obtained allow us to consider ABCP combination therapy an effective strategy for the treatment of advanced NSCLC.
Isaeva et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: